deltatrials
Terminated PHASE2 NCT00005039

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

A Phase II Randomized Trial of Recombinant Fowlpox and Recombinant Vaccinia Virus Expressing PSA in Patients With Adenocarcinoma of the Prostate

Sponsor: National Cancer Institute (NCI)

Conditions Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage IV Prostate Cancer
Interventions laboratory biomarker analysis recombinant fowlpox-prostate specific antigen vaccine recombinant vaccinia prostate-specific antigen vaccine
Updated 6 times since 2017 Last updated: Jan 23, 2013 Started: Jan 31, 2000 Primary completion: Mar 31, 2007

Listed as NCT00005039, this PHASE2 trial focuses on Adenocarcinoma of the Prostate and Recurrent Prostate Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jan 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States